Two Sigma Investments LP Buys 492,934 Shares of GSK plc (NYSE:GSK)

Two Sigma Investments LP grew its stake in GSK plc (NYSE:GSK - Free Report) by 602.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 574,754 shares of the pharmaceutical company's stock after buying an additional 492,934 shares during the period. Two Sigma Investments LP's holdings in GSK were worth $19,438,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in GSK. Indiana Trust & Investment Management Co boosted its holdings in GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after acquiring an additional 500 shares during the last quarter. Crews Bank & Trust acquired a new position in shares of GSK in the 4th quarter worth approximately $26,000. Sierra Ocean LLC bought a new stake in shares of GSK in the 4th quarter valued at $32,000. Parkside Financial Bank & Trust increased its position in shares of GSK by 470.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after buying an additional 818 shares during the period. Finally, Golden State Wealth Management LLC acquired a new stake in shares of GSK during the fourth quarter worth $38,000. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Performance

Shares of GSK opened at $38.91 on Friday. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The stock has a 50-day moving average of $37.31 and a 200-day moving average of $36.01. The company has a market cap of $80.28 billion, a PE ratio of 24.47, a P/E/G ratio of 1.12 and a beta of 0.51. GSK plc has a one year low of $31.72 and a one year high of $45.77.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The business had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same quarter in the prior year, the company earned $0.43 earnings per share. The company's quarterly revenue was up 2.1% on a year-over-year basis. On average, equities research analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be issued a $0.4216 dividend. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.33%. The ex-dividend date is Friday, May 16th. GSK's dividend payout ratio (DPR) is currently 86.60%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on GSK shares. BNP Paribas assumed coverage on shares of GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price on the stock. Morgan Stanley initiated coverage on GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Hsbc Global Res raised GSK to a "strong sell" rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a strong buy rating to the company's stock. According to MarketBeat, GSK has an average rating of "Moderate Buy" and an average price target of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.